[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maimónides Biomedical Research Institute of Córdoba\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":439},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,57,85,121,152,182,217,243,270,294,325,359,385,412],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100641477","ehealth-lifestyle-intervention-to-enhance-outcomes-in-hfpef-100641477",false,"NCT07661732","eHealth Lifestyle Intervention To Enhance Outcomes in HFpEF","Randomized Trial Of A Digital Lifestyle Education Strategy In Patients With Heart Failure And Overweight Or Obesity: The ELITE-HFpEF Study","ELITE-HFpEF","Inclusion Criteria:\n\n* Age over 18 years\n* Body mass index (BMI) over 27 kg\u002Fm²\n* Symptoms consistent with heart failure\n* Left ventricular ejection fraction (LVEF) of 50% or higher\n* Elevated NT-proBNP according to the European Society of Cardiology age-adjusted rule-in thresholds: 125 pg\u002FmL or higher if under 50 years, 250 pg\u002FmL or higher if 50 to 75 years, and 500 pg\u002FmL or higher if 75 years or older\n* Echocardiographic abnormalities: left ventricular hypertrophy, left atrial enlargement, or diastolic dysfunction\n\nExclusion Criteria:\n\n* Body mass index (BMI) over 40 kg\u002Fm²\n* Life expectancy of less than 1 year\n* Chronic kidney disease on renal replacement therapy\n* Moderate or greater valvular heart disease\n* Inability to exercise","ALL","18 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a digital lifestyle education program improves exercise capacity in adults who have heart failure with preserved ejection fraction (HFpEF) and overweight or obesity. HFpEF is a type of heart failure in which the heart muscle is stiff and does not relax well, even though its pumping strength looks normal. The main questions it aims to answer are:\n\n* Does the program improve how much oxygen participants can use during exercise, a measure of fitness, after 6 months?\n* Does the program improve participants' quality of life and help them lose weight?\n\nResearchers will compare a group that uses the digital program plus usual care to a group that receives usual care alone. This will show whether the program adds a benefit.\n\nParticipants will:\n\n* Be placed by chance into one of the two groups\n* Use a study website with short videos on exercise, healthy eating, and managing stress (program group), with new content every week for 6 months\n* Have exercise tests, an ultrasound scan of the heart, blood tests, and complete a quality-of-life questionnaire at the start and after 6 months\n\nBoth groups will keep taking their usual heart failure medicines.",[27,28,29],"Heart Failure and Preserved Ejection Fraction","Obesity & Overweight","Heart Failure",[31,32,33,34,35,36,37,38,39,40,41,42,43],"HFpEF","obesity","overweight","digital health","eHealth","mHealth","telemedicine","web-based intervention","lifestyle intervention","cardiac rehabilitation","Mediterranean diet","cardiopulmonary exercise testing","quality of life","NOT_YET_RECRUITING","2026-06-16",{"date":47,"type":48},"2026-06-22","ACTUAL",{"date":50,"type":21},"2026-09-01",{"date":52,"type":21},"2029-06-30",{"name":54,"class":55},"Maimónides Biomedical Research Institute of Córdoba","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":56},"100576299","phase-3-efficacy-of-the-use-of-neoadjuvant-withwithout-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-locally-advanced-colon-cancer-100576299","NCT06783491","Efficacy of the Use of Neoadjuvant With\u002FWithout Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","Efficacy of the Use of Neoadjuvant With\u002FWithout Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer: A Phase III Multi-arm, Randomized and Controlled Clinical Trial (FOXHIPECT4)","FOXHIPECT4","Inclusion Criteria:\n\n* Patients of both sexes, aged ≥18 years and ≤75 years (patients between 70-75 years old will be discussed in committee).\n* Adenocarcinoma of the colon, sigmoid colon and rectum-sigmoid junction that is cT4a\u002Fb according to the American Joint Committee on Cancer (AJCC) TNM eight edition. Pre-treatment diagnosis by imaging test (CT scan or MRI). High-risk cT3 with invasion into surrounding fat greater than 5mm may be included.\n* Nodal extension: cN0, the presence of cN1\u002F2 according to AJCC TNM 8th edition is allowed as long as they can be resected. Pre-treatment diagnosis by imaging test (CT scan or MRI).\n* Metastatic extension: cM0. Patients with cM1 are not allowed to be included.\n* ECOG 0-1.\n* Microsatellite stability (pMMR).\n* Informed consent duty completed.\n\nExclusion Criteria:\n\n* Presence of metastases (M1). If liver or peritoneal metastases are present at the time of surgery, the patient will be excluded from the study and treated according to the new stage.\n* Presence of un-resectability criteria in the pretreatment work-up, un-resectability will be discussed in MDT with expert oncologic surgeons.\n* Presence of microsatellite instability (dMMR).\n* Presence of deficit of DPD.\n* Urgent intervention due to obstruction or perforation if the primary tumour is removed. Bridge interventions such as transit shunts without removal of the primary tumour or percutaneous drainage of collections prior to neoadjuvant treatment or scheduled surgery will be accepted.\n* Extraperitoneal rectal cancer (medium-low) (avoiding alterations due to neoadjuvant radiotherapy).\n* Coexistence of another relevant malignant neoplastic disease (synchronous colon and rectum-sigmoid tumours are accepted as long as the stage is equal or lower than the treated tumour), it will be discussed in steering committee.\n* Severely impaired hepatic, renal or cardiovascular function.\n* Intolerance to treatment.\n* Gestational or lactating women.","75 Years",{"count":67,"type":21},1083,[69],"PHASE3","The main objective of this randomized and controlled trial is to determine whether the use of a proactive strategy, systemic neoadjuvant treatment (FOLFOX) with or without hyperthermic intraperitoneal chemoterapy (HIPEC) with mitomycin C followed by postoperative systemic adjuvant treatment, increases disease-free survival at 36 months in patients with locally advanced colon cancer compared to standard treatment. Therefore, a phase III, randomized, academic, multicenter, controlled trial will be conducted. Patients with locally advanced colon adenocarcinoma (cT4, cT3 with invasion \\>5mm) Nx and no metastases will be included. Control group (n=361) will receive standard treatment (surgery and adjuvant chemotherapy FOLFOX x 12 based); Experimental group 1 (n=361) = Neoadjuvant chemotherapy (FOLFOX x6) + surgery (associating HIPEC) and FOLFOX x 6; Experimental group 2 (n=361): Neoadjuvant chemotherapy (FOLFOX x6) + surgery and FOLFOX x 6. Randomization will be 1:1:1, stratified and centralized. The primary outcome will be disease-free survival at 36 months. Secondary outcomes will be tumor regression rate, ctDNA negativization, peritoneal relapse rate at 36 months, pattern of relapse, toxicity, morbidity and overall survival. Considering the results obtained with these two independent strategies (FOLFOX and HIPEC), a new trial is justified in order to provide strong evidence for this proactive treatment. The aim is to combine both to obtain a better benefit, which opens the direct possibility of increasing the current percentage of disease-free survival. The results of this study will have important scientific and social impact, since is aimed at improving the outcomes of one subpopulation of patients with locally advanced colon cancer whose current treatment, is not enough to avoid the recurrence of disease.",[72],"Locally Advanced Colorectal Cancer",[74,75],"colorectal cancer","hyperthermic intraperitoneal chemotherapy","RECRUITING","2026-06-04",{"date":79,"type":48},"2026-06-08",{"date":81,"type":48},"2026-05-26",{"date":83,"type":21},"2030-12-31",{"name":54,"class":55},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":17,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":105,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":56},"100635450","effects-of-8-week-crossfit-based-concurrent-training-on-fitness-body-composition-and-psychological-outcomes-in-schoolchildren-100635450","NCT07552844","Effects of 8-Week CrossFit-Based Concurrent Training on Fitness, Body Composition, and Psychological Outcomes in Schoolchildren","Effects of an 8-Week CrossFit-Based Concurrent Training Program on Physical Fitness, Body Composition, and Psychological Outcomes in Schoolchildren: A Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n* Age: 7-11 years.\n* Students enrolled at CEIP Pablo García Baena (Córdoba).\n\nFor the experimental group:\n\n* Availability to attend the Triple XXX Box (Polígono Pedroches, C. los Alfareros, Parcel 119, 14014 Córdoba), where both assessments and training sessions will be conducted.\n* Availability to attend training sessions twice per week for the 8-week intervention period.\n* No participation in extracurricular physical activity prior to the start of the CrossFit program.\n\nFor the control group:\n\nNo participation in extracurricular physical activity. Informed consent signed by parents or legal guardians. No medical, psychological, or behavioral contraindications that would prevent participation in physical activity.\n\nExclusion Criteria:\n\n* Children with musculoskeletal injuries, diseases, or medical, psychological, or behavioral conditions that limit physical activity or interfere with the assessment of outcomes.\n* Inability or anticipated difficulty in regularly attending training sessions.\n* Refusal of parents or legal guardians to provide informed consent.",true,"7 Years","11 Years",{"count":96,"type":21},30,[24],"This study examines the effects of an 8-week CrossFit-based concurrent training program in boys and girls aged 7 to 11 years, comparing an experimental group (n=15) with a control group (n=15). The aim is to assess changes in strength, cardiorespiratory fitness, body composition, and psychological variables such as anxiety, stress, and self-esteem, using field-based physical tests (CMJ, Course Navette, handgrip strength, etc.) and validated questionnaires. The study follows a randomized controlled trial design with pre- and post-intervention assessments. The experimental group will complete two weekly CrossFit sessions adapted for children, while the control group will maintain their usual routine without structured physical training. The hypothesis states that the intervention will significantly improve both physical performance and psychological well-being in the experimental group compared to the control group.",[100,101,102,103,104],"Children","Crossfit","Psychology, Child","Physical Fitness","Body Composition",[106,107,108,109,110,111,103,112],"children","stress","anxiety","exercise training","crossfit","self-esteem","body composition","2026-04-25",{"date":115,"type":48},"2026-04-30",{"date":117,"type":21},"2026-06",{"date":119,"type":21},"2026-07",{"name":54,"class":55},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":56},"100635044","recovery-after-fatigue-in-young-athletes-comparison-between-tecar-therapy-and-cycle-ergometer-100635044","NCT07547566","Recovery After Fatigue in Young Athletes: Comparison Between TECAR Therapy and Cycle Ergometer\"","Immediate and Short-term Effects of TECAR Therapy and Cycle Ergometer on Recovery After Fatigue in Young Athletes: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Engaging in regular physical activity\n* Experience with sports involving jumping or plyometric exercises\n\nExclusion Criteria:\n\n* Performed intense physical exercise within 24 hours before the study\n* Planned to perform intense physical exercise within 24 hours after the study\n* Presence of muscle soreness at the beginning of the study\n* Musculoskeletal injury in the previous 6 months",{"count":129,"type":21},48,[24],"The goal of this clinical trial is to compare two recovery methods after fatigue in young athletes. It aims to find out if tecar therapy (TECAR) or cycle ergometer exercise can improve recovery after intense physical activity and help athletes return to their normal performance more quickly.\n\nThe main questions it aims to answer are:\n\nDoes TECAR or cycle ergometer improve physical performance after fatigue?\n\nDo these methods reduce muscle pain and soreness after fatigue?\n\nResearchers will compare TECAR with active recovery using a cycle ergometer to see which method is more effective.\n\nParticipants will:\n\nPerform a series of jumps to induce fatigue\n\nBe randomly assigned to one of the recovery methods\n\nComplete physical tests before and after fatigue\n\nUndergo simple measurements of muscle condition and pain\n\nReport their level of effort and muscle soreness",[133,134],"Muscle Fatigue","Healthy Adult",[136,133,137,138,139,140,141,142,143],"Muscle Strength","Athletes","Recovery of Function","Countermovement jump","Pressure pain threshold","Muscle soreness","Muscle mechanical properties","Diathermy","2026-04-16",{"date":146,"type":48},"2026-04-23",{"date":148,"type":21},"2026-04",{"date":150,"type":21},"2026-11",{"name":54,"class":55},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":162,"studyType":163,"phases":4,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":56},"100578669","impact-of-cmv-specific-immune-reconstitution-at-the-end-of-letermovir-prophylaxis-on-the-development-of-late-cytomegalovirus-infection-in-hematopoietic-stem-cell-transplant-recipients-inmunoend-100578669","NCT06814301","Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)","Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in HSCT Recipients (INMUNOEND): a Protocol for a Prospective, Observational, Multicenter Study","INMUNOEND","Inclusion Criteria:\n\n* Age \\>18 years.\n* CMV seropositivity (positive IgG) in the recipient at the time of SCT.\n* First allogeneic hematopoietic stem cell transplant recipient (bone marrow, peripheral blood, or cord blood).\n* Within the first 28 days post-SCT at the time of inclusion.\n* Indication for LTV prophylaxis within the first 28 days post-transplant up to 100 days post-SCT, according to the criteria established in each center.\n\nExclusion Criteria:\n\n* CMV seronegativity (negative IgG) in the recipient at the time of transplant.\n* Previous allogeneic stem cell transplant (patients with a prior autologous transplant are allowed to be included).\n* History of CMV disease in the 6 months prior to inclusion.\n* Need for preemptive therapy in the month prior to inclusion in the study.\n* Received any of the following in the 14 days prior to inclusion: Ganciclovir, valganciclovir, foscarnet, acyclovir (at doses \\>3200 mg orally per day or \\>25 mg\u002Fkg IV per day), valacyclovir (at doses \\>3000 mg orally per day), famciclovir (at doses \\>1500 mg orally per day).\n* Received any of the following in the 30 days prior to screening: Cidofovir, CMV hyperimmune immunoglobulin, any CMV antiviral in the investigational phase.\n* Suspected or confirmed hypersensitivity reaction to the LTV formulation or any of its components.\n* Severe hepatic insufficiency (defined as Child-Pugh class C).\n* History of primary immunodeficiency prior to transplant.\n* Participation in a clinical trial involving the administration of CMV vaccines, other investigational CMV drugs, or monoclonal antibodies.",{"count":161,"type":21},123,"200 Days","OBSERVATIONAL","Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) prophylaxis during the first 100 days post-SCT is effective and safe in preventing this infection, although it may be associated with a delay in CMV-specific immune reconstitution. Hence, it is needed a study to evaluate whether the absence of CMV-specific immune reconstitution at the end of LTV prophylaxis is associated with the development of late infection. This could facilitate the individualization of CMV prophylaxis duration in these patients.\n\nMethods and analysis: INMUNOEND is a multicenter, prospective, observational, non-interventional study including CMV seropositive patients undergoing allo-SCT who receive LTV prophylaxis during the first 100 days post-SCT. Immunological and virological monitorization will be conducted until day +200 post-SCT. The primary outcome variable is the percentage of patients who develop clinically significant CMV infection up to day +200 post-SCT after completing LTV prophylaxis. Data collected will include: baseline characteristics of the hematological diseases and comorbidities, variables related to SCT (i.e. engrafment, graft-versus-host disease, use of letermovir and CMV replication) and variables related to CMV-specific immune reconstitution.",[166,167],"Cytomegalovirus Cell Mediated Immunity","Stem Cell Transplantation, Hematopoietic",[169,170,171,172,173],"stem cell transplantation","cytomegalovirus","letermovir","prophylaxis","cytomegalovirus immunity","2025-11-21",{"date":176,"type":48},"2025-11-28",{"date":178,"type":21},"2025-12-01",{"date":180,"type":21},"2027-09",{"name":54,"class":55},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":190,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":201,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100606655","hysteroscopy-anesthesia-for-relief-of-pain-100606655","NCT07178379","Hysteroscopy Anesthesia for Relief of Pain","HARP Trial: Hysteroscopy Anesthesia for Relief of Pain","HARP","Inclusion Criteria\n\n* Age ≥ 18 years: To ensure that participants are legal adults and able to provide informed consent.\n* Indication for office-based diagnostic hysteroscopy: The patient must be scheduled for a diagnostic hysteroscopy, either for uterine cavity evaluation or diagnostic purposes.\n* Simple procedures like uterine polypectomies involving 1, 2, or more than 3 polyps or endometrial biopsy\n* No previous hysteroscopies\n\nExclusion Criteria\n\n* Age \\\u003C 18 years\n* Known allergy to any local anesthetic\n* General contraindications to hysteroscopy including pregnancy (established via interview, last menstrual period, contraceptive use, or pregnancy test), active infection (e.g., pyometra or recent pelvic inflammatory disease), recent uterine perforation, etc.\n* Complex procedures like myomectomy with morcellator\n* Failure to access the uterine cavity\n* Anatomic conditions preventing cavity access\n* Excessive procedure duration or fluid use (fluid deficit \\> 1000 cc)\n* Known uterine malformations\n* Waiting times exceeding 60 minutes\n* Use of analgesic medication prior to the procedure\n* Major complications related to the procedure including uterine perforation, creation of a false passage, or significant bleeding requiring interventions beyond standard care.\n* Incomplete delivery of informed consent or failure to complete the pre-procedure anxiety questionnaire.","FEMALE",{"count":192,"type":21},70,[24],"This randomized clinical trial aims to evaluate the effect of local anesthesia on pain perception in patients undergoing outpatient diagnostic hysteroscopy. Although generally well tolerated, pain during hysteroscopy remains a leading cause of procedural failure and patient discomfort. Current evidence on the effectiveness of local anesthetic techniques is limited, with considerable variability in study designs, patient populations, and outcomes measured.\n\nThis study will compare pain levels between two groups: one receiving local anesthetic infiltration (3% mepivacaine into the uterosacral ligaments), and the other undergoing a placebo-like intervention (saline irrigation without injection). Pain will be assessed using a standardized Visual Analog Scale (VAS).\n\nThe primary objective is to determine whether local anesthesia significantly reduces pain perception during the procedure. Secondary objectives include evaluating which patient or procedural variables may influence pain (e.g., parity, uterine position, BMI, operator experience) and whether local anesthesia impacts the need for post-procedural analgesia or complication rates.\n\nPatients will be randomly assigned in a 1:1 ratio using a simple randomization method. Although the study design does not allow for double blinding, efforts will be made to minimize expectation bias-patients will not be explicitly informed whether they are receiving anesthesia or not, and the placebo group will receive simulated intervention. The principal investigator and the statistician will be blinded to the treatment allocation during data analysis.\n\nInclusion criteria are: age ≥ 18 years, indication for office-based diagnostic hysteroscopy or minor operative procedures (e.g., polypectomy or biopsy), and no previous hysteroscopy experience. Exclusion criteria include known anesthetic allergy, complex procedures (e.g., myomectomy), anatomic uterine malformations, severe complications, or lack of consent.\n\nA total sample size of 58 patients (29 per group) has been calculated based on an expected clinically relevant VAS difference of 1.5 points and a standard deviation of 2.0. To account for possible dropouts, up to 70 patients may be enrolled.\n\nThe results of this trial will provide higher quality evidence on whether local anesthesia should be routinely recommended in outpatient hysteroscopy and may support cost-effectiveness studies in the future.",[196,197,198,199,200],"Pain Management","Outpatient Hysteroscopy","Local Anesthesia","Procedural Pain Relief","Gynecologic Procedure",[202,203,204,205,206,207,208],"hysteroscoy","outpatient hysteroscopy","pain assessment","visual analog scale","localanesthesia","ambulatory surgery","randomized controlled trial","2025-09-10",{"date":211,"type":48},"2025-09-17",{"date":213,"type":21},"2025-09-06",{"date":215,"type":21},"2025-12-31",{"name":54,"class":55},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100597497","early-diagnosis-of-heart-failure-using-nt-probnp-levels-in-primary-care-100597497","NCT07059260","Early Diagnosis of Heart Failure Using NT-proBNP Levels in Primary Care","Early Diagnosis of Heart Failure Using NT-proBNP Levels in Primary Care: The EARLY-BNP Study","EARLY-BNP","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Signs and symptoms related to heart failure (HF).\n* Patients assessed in primary care.\n* No prior diagnosis of HF.\n* NT-proBNP levels \\> 300 pg\u002FmL.\n\nExclusion Criteria:\n\n* Patients diagnosed with a chronic disease with persistently elevated NT-proBNP levels, assessed by Cardiology, in whom heart failure (HF) has been ruled out in the previous year (mainly by echocardiography).\n* Chronic kidney disease on hemodialysis.\n* Patients with a life expectancy of less than 1 year due to severe comorbidities such as advanced-stage cancer.\n* Patients enrolled in other clinical trials.\n* Inability of the patient to understand the clinical trial and to provide informed consent.",{"count":226,"type":21},304,[24],"Heart failure (HF) is a growing public health problem, expected to increase in prevalence and incidence due to population aging. This challenge is compounded by the healthcare overload following the COVID-19 pandemic, particularly in primary care (PC). Early diagnosis of HF is critical for improving outcomes, reducing complications, and optimizing resource use. However, there is no robust scientific evidence supporting the effectiveness of early screening for HF in PC settings.\n\nThis study aims to evaluate whether an early cardiology assessment model for patients with suspected HF and elevated NT-proBNP levels (\\>300 pg\u002FmL) improves clinical outcomes compared to the standard referral pathway. The hypothesis is that early intervention will reduce emergency visits, hospitalizations, and mortality related to HF.\n\nThis is a prospective, single-center, open-label, phase II randomized controlled trial with parallel group allocation (1:1). Patients presenting to PC with HF symptoms and no prior HF diagnosis, who have NT-proBNP levels \\>300 pg\u002FmL, will be invited to participate. After informed consent, participants will be randomized to one of two groups:\n\n* Intervention group: Early cardiology assessment within 7 days.\n* Control group: Standard referral by PC physician per usual care.\n\nRandomization will be computer-generated and managed independently to ensure allocation concealment. Patients will be followed for 12 months from the date of NT-proBNP testing. Outcomes will be collected through both cardiology and PC visits.\n\nOur primary outcome measure will be the clinical benefit, defined as a hierarchical composite endpoint of:\n\n1. Cardiovascular mortality\n2. All-cause mortality\n3. Number of hospitalizations due to HF\n4. Number of urgent care visits due to HF\n5. Number of GDMT (Guideline-Directed Medical Therapy) drugs initiated\n6. Number of GDMT drugs with dose escalation\n7. Proportional change in log (NT-proBNP) at 12 months\n\nThe primary analysis will use a win ratio methodology to maximize statistical efficiency and clinical interpretability.\n\nSecondary outcomes include:\n\n* Each component of the primary endpoint\n* Stratified analysis by confirmed or excluded HF diagnosis\n* Stratified analysis by HF phenotype (HFrEF vs HFpEF)\n* Stratified analysis by sex\n\nA sample size of 304 patients (152 per group) has been calculated to detect a win ratio of 1.7 with 80% power, based on expected clinical benefit and statistical assumptions from prior literature. The study is expected to complete recruitment within 12 months, with a total study duration of 24 months including follow-up and data analysis.",[29],[29,231,232,233,234],"Primary Care","Cardiology","NT-proBNP","proBNP","2025-07-07",{"date":237,"type":48},"2025-07-10",{"date":239,"type":21},"2025-09",{"date":241,"type":21},"2027-12",{"name":54,"class":55},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":92,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":252,"conditions":253,"keywords":256,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":56},"100570841","biomarkers-in-ev-associated-with-marrow-adiposity-in-anorexia-100570841","NCT06712485","Biomarkers in EV Associated With Marrow Adiposity in Anorexia","Identification of Biomarkers in Extracellular Vesicles Associated With Marrow Adiposity and Bone Deterioration Caused by Nutritional Deficiencies","VE_BMAT_AN","Inclusion Criteria:\n\nFor AN group:\n\n* Diagnosis of active AN according to DSM-5 criteria\n* BMI of less than 17kg\u002Fm2\n* Present amenorrhoea in the 3 months prior to the start of the study.\n\nFor AN-R group:\n\n* Achieved weight gain of more than 85%.\n* Normal menstruation in the last 3 months.\n\nFor Control group:\n\n* Population of the same age and gender as the AN and AN-R groups.\n* If pubertal population, presenting a chronological age of ± 2 years.\n* Normal menstruation\n* Normal BMI (\\>18.5 kg\u002Fm2)\n* No presence of previous dietary transtrons.\n\nExclusion Criteria:\n\n* Not receiving oestrogens, contraceptives or glucocorticoids in the 3 months prior to the start of the study.\n* Not to suffer from chronic diseases, such as diabetes, pathologies affecting the bone system or thyroid function.\n* Do not take calcium or vitamin supplements.",{"count":96,"type":21},"The aim of this observational study is to identify biomarkers in extracellular vesicles associated with medullary adiposity occurring in patients with anorexia nervosa. The main question it aims to answer is:\n\nCan this medullary adiposity be associated with the bone deterioration observed in this population?\n\nParticipants will be assessed for body composition and a blood sample will be taken by non-invasive techniques.",[254,255],"Anorexia Nervosa Restricting Type","Anorexia Nervosa (DSM-IV Revised Criteria)",[257,258,259,260,261],"Extracellular Vesicles","Bone Deterioration","Biomarkers","Bone Marrow Adipose Tissue","Nutritional Deficiencies","2025-05-05",{"date":264,"type":48},"2025-05-07",{"date":266,"type":21},"2025-05-15",{"date":268,"type":21},"2026-07-31",{"name":54,"class":55},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":56},"100517317","omega-3-fatty-acids-and-nutritional-support-in-gastrointestinal-cancer-100517317","NCT06015971","Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer","Omega-3 Enriched Supplements in the Nutritional Support of Patients With Gastrointestinal Cancer","Inclusion Criteria:\n\n* \\- Patients with Gastrointestinal tumor undergoing systemic treatment (chemo-radio-immuno therapy or their combination)\n* Body weight loss \\>5% in the previous three months or \\>10% in the previous six months\n* Both sexes\n* Age between 18-85 y-old.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C 2 weeks\n* MDRD \\\u003C 15 mL\u002Fmin\n* End-stage liver disease\n* Any musculoskeletal, cardiovascular and\u002For neurological disorders that could affect exercising.",{"count":278,"type":21},40,[24],"Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, in consequence, quality of life of these patients decreases while morbidity, mortality and costs increase. In this context, appropriate nutritional screening and early nutrition support are extremely recommended, to this aim, in some cases, oral nutritional supplements (ONS) are necessary; ONS could have a standard formula or be enriched with specific nutrients (arginine, glutamine, branched chain amino acids, n-3 fatty acids, and nucleotides), which can modulate the activity of the immune system and provide an additional benefit beyond the nutritional support, this intervention type is called immunonutrition. Despite these possible benefits, their utility has been proven in few clinical scenarios, for example in with patients with upper gastrointestinal cancer undergoing surgical resection; based on this, current guidelines recommend that patients should receive oral\u002Fenteral nutritional support with an specific formula enriched in immunonutrients (with arginine, n-3 fatty acids or nucleotides) , but there is a lack of evidence for supporting its use in other clinical conditions including patients with cancer that receive systemic treatment",[282],"Sarcopenia",[284,285,286],"cancer","nutritional support","omega-3 enriched nutritional supplements",{"date":288,"type":48},"2025-05-06",{"date":290,"type":48},"2023-07-01",{"date":292,"type":21},"2026-12-31",{"name":54,"class":55},{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":301,"enrollmentInfo":302,"targetDuration":304,"studyType":163,"phases":4,"briefSummary":305,"conditions":306,"keywords":310,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":56},"100466637","fgf23-and-cardiovascular-damage-in-anemia-with-an-without-chronic-kidney-disease-100466637","NCT05356325","FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.","The Role of FGF23 on the Induction of Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease","Inclusion Criteria:\n\n* Hemoglobin \\\u003C 11g\u002Fdl\n* Serum ferritin \\\u003C 100 ng\u002Fml or transferrin saturation index \\\u003C 20%\n\nExclusion Criteria:\n\n* Weight \\\u003C 50 Kg or BMI \\\u003C 17\n* Acute bleeding \\> 500 ml, within 72 hours before study inclusion\n* Proliferative hematologic disease. Hemochromatosis\n* Active infections within 30 days before study inclusion\n* Systemic inflammatory illness\n* Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV) infection\n* Iron active treatment\n* Blood transfusion in the last 90 days before inclusion.\n* Cardiovascular hospitalization 30 days before study inclusion\n* Anticoagulant treatment with coumarins\n* Chronic liver disease\n* Immunosuppressive therapy\n* Erythropoiesis stimulating agents treatment, radiotherapy or chemiotherapy within 30 days before inclusion\n* Scheduled major surgery during study period\n* Pregnancy or lactation\n* Drugs addiction\n* Participation in others clinical trials.","85 Years",{"count":303,"type":21},401,"3 Months","Anemia is associated with cardiovascular disease. Iron deficiency is usually induced in chronic kidney disease (CKD). In clinical studies, an inverse association between serum levels of iron and fibroblast growth factor 23 (FGF23), a cardiovascular risk factor, has been demonstrated. In addition, a number of the I.V. iron presentations mostly used to treat anemia show unwanted side effects related to phosphate alterations and increased FGF23. Objectives. The General Objective of this project is to evaluate, through in vivo and in vitro studies, the cardiovascular alterations related to the anemia-induced increase in FGF23 production; as well as the identification of possible molecular targets that may be useful in its prevention and\u002For palliation. Specific Objectives are: 1) To determine in a population with anemia (due to iron deficiency), with and without CKD, an association between the parameters related to iron metabolism, FGF23 and markers of cardiovascular damage. 2) To evaluate in vivo, in a murine experimental model of anemia, with and without CKD, the effects of the modulation (inhibition) of triggers of iron deficiency (hepcidin) and of the increase in FGF23 (HF1α), on markers of cardiovascular damage. 3) To compare in vivo, in an experimental model of anemia with and without CKD, the effect of different I.V. iron presentations (ferrous sulphate, ferric carboxymaltose and ferric citrate) on FGF23 levels and their cardiovascular impact. 4) To evaluate in vitro, in cardiomyocytes cultures, in the presence of iron deficiency, the direct effect of FGF23 on the induction of cardiac damage. 5) To evaluate in vitro, in osteoblasts cultures, the direct effect of ferrous sulphate, ferric carboxymaltose, ferric citrate and hepcidin. Methodology. The levels of intact and C-terminal FGF23 (FGF23i and FGF23c), the differential expression profile of plasma miRNAS and of proteomic, markers of cardiovascular disease, mineral metabolism, inflammation and oxidative stress and intracellular signalling pathways will be evaluated.",[307,308,309],"Fibroblast Growth Factor 23","Anemia","CKD",[311,312,309,313,314,315,316],"FGF23","anemia","iron deficiency","cardiovascular risk","miRNAS","inflammation","2025-02-06",{"date":319,"type":48},"2025-02-07",{"date":321,"type":48},"2021-10-18",{"date":323,"type":21},"2025-07-01",{"name":54,"class":55},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":92,"sex":17,"minAge":333,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":358},"100576643","exploring-minor-proteins-and-peptides-in-human-milk-a-proteomic-analysis-across-lactation-stages-100576643","NCT06787963","Exploring Minor Proteins and Peptides in Human Milk: a Proteomic Analysis Across Lactation Stages","Quantitative Proteomic Analysis of Minor Whey Proteins and Peptides of Human Milk Across Five Neonatal Groups Classified by Birth Weight During the Three Stages of Lactation","PROTEOM-MILK","Inclusion Criteria:\n\n* Healthy mothers\n* With monitored pregnancies within the care area of the Reina Sofía University Hospital in Córdoba\n* With newborns expected to be exclusively breastfed until 4 months\n\nExclusion Criteria:\n\n* Mothers whose newborns have any of the following conditions: congenital malformation, chromosomal abnormality, hypoxia-ischemia, gastroschisis, polycythemia, hypoglycemia, sepsis, blood incompatibility\n* Pathological pregnancy, pregnancy by in vitro fertilization, or multiple pregnancies\n* With no plan to exclusively breastfeed until 4 months\n* Under medical treatment\n* Have a drug addiction\n* Refuse informed consent\n* Have had previous breast surgery\n* Live outside the metropolitan area","0 Days","120 Days",{"count":336,"type":21},150,"Human milk (HM) is the optimal food source for the nutrition, growth, and development of newborns. The protein fraction of HM plays a crucial role in the healthy development of infants. HM contains a wide variety of minor whey proteins and peptides with important bioactive functions, many of which are still unknown. Proteomics allows for the study of biological samples with inherently complex protein mixtures. Proteins are essential for the development of living organisms, both in quantitative and qualitative terms. The combination of proteomic techniques currently enables the study of protein variability and minor peptides in HM across different lactation stages and allows for differential quantification according to gestational age and birth weight. However, studies on the human milk serum proteome during these stages are limited. The aim is to explore the minor whey proteins and peptides in human milk through a longitudinal analysis of five groups of breastfeeding mothers (with 30 extremely low birth weight newborns, 30 very low birth weight newborns, 30 low birth weight newborns, 30 adequate birth weight newborns, and 30 high birth weight newborns). Gestational age will also be considered to ensure homogeneous group distribution according to this condition. HM samples will be collected from each mother during three lactation periods after birth: within the first 48 hours (colostrum), at 5-14 days (transitional milk), and at 100-120 days (mature milk) for the five birth weight groups. In these neonatal\u002Finfant groups, minor proteins from whey fraction and peptides will be separated, quantified, and identified using label-free proteomic techniques. This study aims to expand our understanding of the minor proteins and peptides in human milk and their bioactive roles in neonatal health. By examining these components across different birth weight groups and lactation stages, the research will offer insights into how protein and peptide profiles vary by gestational age and birth weight, potentially influencing neonatal development. The findings from this proteomic analysis could not only demonstrate the complexity of human milk composition but also contribute to targeted nutritional support for preterm or low-birth-weight infants, customizing protein supplementation in HM banks and therefore enhancing their growth and developmental outcomes.",[339,340,341],"Low Birthweight Infant","Preterm","Very Low Birth Weight Preterms",[343,344,345,346,347,348,349,350],"low birth weight","prematurity","gestational age","human milk","bioactive peptides","proteomics","lactation","whey protein","2025-01-16",{"date":353,"type":48},"2025-01-22",{"date":355,"type":48},"2024-12-02",{"date":241,"type":21},{"name":54,"class":55},2,{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":4},"100560645","phase-4-12-month-efficacy-of-exercise-and-cytisinicline-for-tobacco-abstinence-100560645","NCT06579846","12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence","Multicenter Experimental Study to Evaluate the Efficacy in Tobacco AbstinEnce At 12 Months of DIrected Exercise and CyTisinicline","MEDSEC-CTA12","Inclusion Criteria:\n\n* Aged between 18 and 65 years.\n* Smoking a minimum of 10 cigarettes per day.\n* In the contemplation or action stage according to Prochaska and DiClemente's Transtheoretical Model.\n* Prepared to initiate smoking cessation treatment imminently and with commitment.\n* Demonstrating a high level of nicotine dependence, with a Fagerström test score of 7 or higher.\n* Exhibiting significant motivation to quit smoking, as indicated by a Richmond test score of 6 or higher.\n* Having made at least one prior attempt to quit smoking within the past year.\n* Enrolled in or covered by the Andalusian Public Health System.\n\nExclusion Criteria:\n\n* Individuals with medical conditions that contraindicate participation in physical exercise, including but not limited to malignant hypertension, heart failure, hyperthyroidism, peripheral arterial disease, or other conditions deemed by the research team to pose a risk of adverse events or significantly impair adherence to the study.\n* Individuals who have experienced changes in their usual treatment regimen within the past 90 days.\n* Individuals unable to provide informed consent.\n* Individuals with pathological conditions that significantly reduce life expectancy to less than 5 years.\n* Individuals with contraindications as specified in the product information for cytisinicline , such as pregnancy, breastfeeding, hypersensitivity to cytisinicline, unstable angina, recent myocardial infarction, clinically significant arrhythmias, or recent stroke.","65 Years",{"count":336,"type":21},[370],"PHASE4","Current scientific evidence demonstrates the relationship between good physical fitness and a lower incidence of certain chronic diseases, including smoking, as well as the effectiveness of cytisinicline. This protocol aims to evaluate the efficacy of the synergistic effect of combining structured physical exercise, brief counseling, and cytisinicline administration in achieving smoking cessation. The study will be an experimental, multicenter, randomized, and controlled trial with two parallel arms, conducted by a multidisciplinary team within the primary care setting of the Andalusian public health system, with a 12-month follow-up. The estimated sample size is 75 participants per arm. One of the study arms will include a structured exercise program aligned with the recently approved regional Andalusian health plan.",[373],"Smoking Cessation",[375,376,377],"Tabacco","Cytisinicline","Exercise","2024-08-30",{"date":380,"type":48},"2024-09-04",{"date":382,"type":21},"2025-01-01",{"date":215,"type":21},{"name":54,"class":55},{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":17,"minAge":392,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":22,"phases":396,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":56},"100551232","programme-for-intervention-in-paediatric-obesity-100551232","NCT06457412","Programme for Intervention in Paediatric Obesity","PinPo","Inclusion Criteria:\n\n* Children between 6 and 12 years old, with a BMI greater than the 99th percentile according to Cole criteria (2004).\n\nExclusion Criteria:\n\n* Children \\\u003C 6, or \\> 12 years.\n* Children with chronic diseases or following a therapeutic diet.\n* Children with intervention in other centers.","6 Years","12 Years",{"count":395,"type":21},200,[24],"The PinPo program aims to carry out a comprehensive intervention for children aged 6 to 12 years with childhood obesity (with a BMI greater than the 99th percentile), fostering motivation and encouraging changes toward healthy lifestyle habits to achieve greater adherence and improved health. The program comprises 9 educational sessions designed by specialized professionals from various disciplines (pediatrics, psychology, nursing, nutrition), for a group of 10 children and another group of 10 family members and\u002For caregivers. These sessions are conducted in a hospital setting every 15 days, each lasting 90 minutes.",[399],"Obesity, Childhood",[401,402,403],"Obesity","Childhood","Grupal intervention","2024-06-07",{"date":406,"type":48},"2024-06-13",{"date":408,"type":48},"2022-03-01",{"date":410,"type":21},"2032-03-01",{"name":54,"class":55},{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":422,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":56},"100520486","phase-2-efficacy-of-letermovir-in-preventing-cytomegalovirus-cmv-infection-in-lung-transplant-recipients-vs-valganciclovir-100520486","NCT06057194","Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.","Prospective Study to Assess the Efficacy of Letermovir Prophylaxis in Preventing CMV Infection in Lung Transplant Recipients Compared to a Retrospective Cohort Treated With Standard Valganciclovir Prophylaxis for 12 Months (LETERCOR Study)","LETERCOR","Inclusion Criteria (prospective cohort):\n\n* Adults over 18 years old\n* Lung transplant recipients (D+\u002FR-) pre-transplant.\n* Having an undetectable CMV polymerase chain reaction assay (PCR) within the 96 hours prior to the start of letermovir prophylaxis.\n* Patients who have provided written informed consent.\n\nExclusion Criteria (prospective cohort):\n\n* HIV-infected patients.\n* Patients with multivisceral transplant.\n* Patients unable to comply with the follow-up protocol.\n* Receiving a different antiviral prophylaxis other than ganciclovir prior to letermovir prophylaxis.\n* Patients with concurrent renal and hepatic insufficiency.\n\nInclusion Criteria (retrospective cohort):\n\n* Adults over 18 years old. Lung transplant recipients (D+\u002FR-) pre-transplant.\n* Patients treated with Valganciclovir prophylaxis for 12 months.\n* Patients transplanted within 2 years prior to the start of the study.\n* Patients with a complete 13-month follow-up and comparable data to the prospective cohort to evaluate the study's primary variables.\n\nExclusion Criteria (retrospective cohort):\n\n* HIV-infected patients.\n* Patients with multivisceral transplant.",{"count":421,"type":21},90,[423],"PHASE2","The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+\u002FR-) compared to a historical cohort of lung transplant recipients (D+\u002FR-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease.\"",[426],"Infections, Cytomegalovirus",[428,429,430],"Lung transplant","CMV prophylaxis","Cytomegalovirus","2023-09-25",{"date":433,"type":48},"2023-09-28",{"date":435,"type":21},"2023-10",{"date":437,"type":21},"2027-04",{"name":54,"class":55},""]